Cargando…

Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp

Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfarouk, Khalid O, Stock, Christian-Martin, Taylor, Sophie, Walsh, Megan, Muddathir, Abdel Khalig, Verduzco, Daniel, Bashir, Adil H H, Mohammed, Osama Y, Elhassan, Gamal O, Harguindey, Salvador, Reshkin, Stephan J, Ibrahim, Muntaser E, Rauch, Cyril
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502609/
https://www.ncbi.nlm.nih.gov/pubmed/26180516
http://dx.doi.org/10.1186/s12935-015-0221-1
Descripción
Sumario:Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer.